HC Wainwright Has Bullish Forecast for UNCY FY2029 Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Research analysts at HC Wainwright increased their FY2029 earnings per share estimates for shares of Unicycive Therapeutics in a research report issued to clients and investors on Thursday, November 13th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of $7.99 per share for the year, up from their previous forecast of $7.61. HC Wainwright has a “Buy” rating and a $22.00 price target on the stock. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.23) per share.

Unicycive Therapeutics (NASDAQ:UNCY) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.20.

Other equities analysts also recently issued reports about the stock. Benchmark lifted their price target on shares of Unicycive Therapeutics to $21.00 and gave the company a “speculative buy” rating in a report on Monday, September 15th. Wall Street Zen raised shares of Unicycive Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, November 2nd. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Unicycive Therapeutics in a report on Thursday, October 30th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Unicycive Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $34.33.

Unicycive Therapeutics Stock Performance

Shares of NASDAQ:UNCY traded up $0.40 on Friday, hitting $5.73. The stock had a trading volume of 728,058 shares, compared to its average volume of 396,448. The firm’s 50 day moving average price is $4.51 and its 200-day moving average price is $5.09. Unicycive Therapeutics has a twelve month low of $3.71 and a twelve month high of $11.00. The company has a market capitalization of $101.20 million, a price-to-earnings ratio of -1.46 and a beta of 1.87.

Institutional Investors Weigh In On Unicycive Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vivo Capital LLC lifted its position in shares of Unicycive Therapeutics by 14.0% during the first quarter. Vivo Capital LLC now owns 11,370,152 shares of the company’s stock worth $6,537,000 after purchasing an additional 1,400,000 shares in the last quarter. Vanguard Group Inc. boosted its position in Unicycive Therapeutics by 8.7% in the 3rd quarter. Vanguard Group Inc. now owns 658,878 shares of the company’s stock valued at $2,873,000 after buying an additional 52,925 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in shares of Unicycive Therapeutics in the 3rd quarter valued at $512,000. JPMorgan Chase & Co. raised its position in shares of Unicycive Therapeutics by 11,698.4% during the second quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock worth $104,000 after acquiring an additional 21,525 shares during the last quarter. Finally, Lazard Asset Management LLC acquired a new position in shares of Unicycive Therapeutics during the second quarter valued at $55,000. Institutional investors and hedge funds own 40.42% of the company’s stock.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.